Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

454
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
454
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

360
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
360
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

620
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
620
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

309
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
309
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

469
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
469
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

340
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
340

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations.

Blood reviews·2019
Same author

Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients.

Blood cancer journal·2016
Same author

Antiphospholipid Antibodies and Associated Clinical Manifestations.

Hematology (Amsterdam, Netherlands)·2016
Same author

The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances.

Blood reviews·2016
Same author

PO-19 - Platelet (PLT) adhesion under flow condition in essential thrombocythemia (ET) and polycythemia vera (PV) is variably influenced according to patient mutational status.

Thrombosis research·2016
Same author

PO-26 - Whole blood rotational thromboelastometry (ROTEM) to detect hypercoagulability in patients with myeloproliferative neoplasms (MPN).

Thrombosis research·2016

Related Experiment Video

Updated: Mar 18, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.6K

The Management of Essential Thrombocythaemia.

T Barbui1, G Finazzi1, T C Pearson2

  • 1a Divisione di Ematologia , Ospedali Riuniti , Bergamo , Italy Division of Haematology , St Thomas' Hospital , London , UK .

Hematology (Amsterdam, Netherlands)
|July 14, 2016
PubMed
Summary
This summary is machine-generated.

Essential thrombocythemia (ET) management focuses on preventing thromboembolic events. Hydroxyurea is a preferred treatment for high-risk ET patients, while younger individuals may benefit from observation or antiplatelet therapy.

Keywords:
Essential ThrombocythaemiaHaemorrhageThrombosisTreatment

More Related Videos

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

20.6K

Related Experiment Videos

Last Updated: Mar 18, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.6K
Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

20.6K

Area of Science:

  • Hematology
  • Oncology
  • Internal Medicine

Background:

  • Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by elevated platelet counts.
  • While often having a benign course, ET carries a significant risk of thromboembolic complications, particularly in older patients or those with prior thrombosis.
  • Current therapeutic strategies aim to mitigate morbidity and mortality associated with ET.

Purpose of the Study:

  • To review the current therapeutic options for essential thrombocythemia.
  • To delineate treatment strategies based on patient age, history, and symptoms.
  • To highlight the role of hydroxyurea and other agents in managing ET.

Main Methods:

  • Review of existing clinical practice guidelines and therapeutic evidence for essential thrombocythemia.
  • Analysis of treatment indications based on patient risk factors such as age, thrombosis history, and platelet count.
  • Evaluation of the efficacy and safety profiles of cytoreductive agents (hydroxyurea, interferon, anagrelide) and antiplatelet drugs.

Main Results:

  • Hydroxyurea is recommended for patients over 60, with a history of thrombosis or bleeding, or extremely high platelet counts (>1,000 X 10(9)/L).
  • Hydroxyurea has demonstrated efficacy in reducing both platelet count and thromboembolic complications.
  • Low-dose aspirin may be used adjunctively for thrombosis or microvascular disturbances. Observation or antiplatelet therapy is considered for younger, asymptomatic patients.
  • Interferon or anagrelide are potential alternatives, particularly given concerns about hydroxyurea's risk of leukemia transformation.

Conclusions:

  • Treatment decisions for essential thrombocythemia are individualized, considering patient-specific factors.
  • Hydroxyurea is the current treatment of choice for high-risk ET patients due to its proven benefits in reducing thrombotic events.
  • Further research into alternative therapies like interferon and anagrelide is warranted, especially concerning long-term safety and potential risks.